By Aaron Seibert
Veterans with severe PTSD and depression are increasingly traveling overseas for treatments they cannot legally access in the United States.
After exhausting medications and conventional treatments, many are traveling to clinics in countries like Mexico to pursue psychedelic-assisted treatments. Others are seeking underground providers outside any regulated medical system.
That should concern everyone – not because these treatments are necessarily unsafe, but because veterans are being pushed outside the safeguards of the American healthcare system to access them.
If promising medicines exist, the United States has a responsibility to study them and, if they prove safe and effective, make them available through a regulated system here at home.
Today, too many veterans have nowhere safe to turn. Seventeen veterans die by suicide each day in the United States. Many more live with PTSD and depression that existing treatments fail to address.
These are stubborn, complex conditions. Many veterans spend years cycling through medications, therapy programs, and referrals with little meaningful relief.
It has been more than 25 years since the United States has approved a new treatment for PTSD. With conventional treatments failing, some veterans are traveling overseas to access psychedelic-assisted treatments being used abroad.
Veterans are navigating unfamiliar providers and inconsistent standards because they believe these treatments may offer their best chance at recovery.
But seeking care abroad comes with a lot of risks. For starters, it’s harder to verify if a provider has a legitimate medical license or credentials.
Many of these clinics operate outside the oversight and safeguards of the U.S. medical system. As CBS News has reported, there are no standardized health screenings before treatment, required monitoring protocols, or requirements to track adverse effects. That wouldn’t be the case on American soil.
It is time to create a safe, regulated pathway for veterans to access these medicines within the protections of the American medical system.
For decades, skepticism surrounding psychedelic compounds largely shut down research in the United States. But over the past twenty years, that has begun to change. Major academic institutions have restarted carefully controlled clinical studies.
Governments and regulators are beginning to respond. In 2023, Australia became the first country to permit limited clinical use of MDMA and psilocybin under strict psychiatric supervision. U.S. policymakers have recently shown greater openness to expanding psychedelic research.
The clinical evidence continues to grow. Psilocybin medicine has produced rapid reductions in symptoms of major depression. MDMA-assisted treatment has shown substantial reductions in PTSD symptoms. In one trial, 67% of participants no longer met the diagnostic criteria for PTSD after treatment.
These treatments are being held to the same scientific and regulatory standards applied to any other medicine seeking approval. Nothing should move forward without rigorous FDA review. But if research continues to demonstrate strong results, veterans should not be forced to leave the country to access care that may help them heal.
Veterans are already seeking these treatments. The real question is where – and under what conditions – they receive them.
They deserve the safest option.
Aaron Q. Seibert serves as a Wounded Warrior liaison, host of the “Combat Vet Vision” podcast, vice president of the Warrior Built Foundation, and heads the West Coast offices of the PTSD Foundation of America. He served three combat tours as a Navy Corpsman and is the recipient of a Purple Heart.